PRESS RELEASE published on 01/04/2024 at 13:05, 2 years 10 months ago A2Z Smart Technologies Corp. Announces Aggregate US$4.7 Million Registered Direct Offering of Common Shares and Common Warrants, Inclusive of $1.5 Million Raised in December 2023 A2Z Smart Technologies Corp. has announced a definitive securities purchase agreement to issue common shares and warrants in a registered direct offering, expecting to raise aggregate gross proceeds equal to US$3.23 million. The net proceeds will be used for working capital and general corporate purposes. The offering is subject to customary closing conditions and is expected to close on or around Monday, January 8, 2024. Common Shares A2Z Smart Technologies Corp. Securities Purchase Agreement Registered Direct Offering Warrants
PRESS RELEASE published on 01/04/2024 at 13:00, 2 years 10 months ago Pulsar Announces Investor Awareness Agreements Pulsar Helium Inc. (TSXV:PLSR) has entered into advertising and investor awareness campaign agreements with Tailfin Capital, Miriad Limited, Martin City Studios, GoldInvest Consulting, and NAI Interactive. These agreements aim to enhance market and brand awareness, investor engagement, and shareholder connections. The agreements include a variety of services such as digital media, marketing, data analytics, investor relations, media, consultancy, audio interviews, investor relation services, and public relations. The company's president and CEO, Thomas Abraham-James, expressed excitement for the comprehensive strategy's implementation in 2024 and emphasized its potential impact during an active time for Pulsar. Brand Awareness Pulsar Helium Inc. Advertising Agreements Investor Awareness Market Engagement
PRESS RELEASE published on 01/04/2024 at 13:00, 2 years 10 months ago Eagle Plains Announces Management Transition Eagle Plains Resources Ltd. (TSXV:EPL) has announced a planned senior management transition to lead the company into the coming years. The transition includes the resignation of Tim J. Termuende as President and CEO, the appointment of Charles C. (Chuck) Downie as President and CEO, the addition of Jesse T. Campbell to the Board of Directors, and changes in roles for other key personnel. The company remains financially healthy with significant cash in treasury, investments, and real estate assets, and continues to pursue mineral exploration projects with a focus on critical metals in western Canada. For further information, please visit their website. Eagle Plains Resources Ltd Senior Management Transition Mineral Exploration EPL Western Canada
PRESS RELEASE published on 01/04/2024 at 13:00, 2 years 10 months ago Shareholder Update: Review of 2023 and Outlook for 2024 Aztec Minerals Corp. (TSXV:AZT)(OTCQB:AZZTF) provides a review of 2023 and its outlook for 2024, highlighting advancements in its projects and corporate side, including the Tombstone Project's drilling program and the Cervantes Project's exploration program. The company appointed a new CFO, raised $2.6 million in equity financings, and is well positioned to create substantial shareholder value in 2024. The press release also provides details on the 2023 highlights and the 2024 outlook for Aztec Minerals Corp. Aztec Minerals Corp Tombstone Project Cervantes Project Precious Metals Discoveries Equity Financings
PRESS RELEASE published on 01/04/2024 at 12:30, 2 years 10 months ago Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece Zomedica Corp. announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients without sedation. The article describes the use of a novel shockwave trode, reinforcing current clinical evidence on the effectiveness of electro-hydraulic shock wave therapy for various indications. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available on Frontiers in Veterinary Science. In addition, CSU is evaluating PulseVet therapy for slowing the progression of canine osteoarthritis, with expected results later in 2024. The ability to treat patients without sedation using X-Trode is seen as a major advancement. Zomedica's Vice President of Clinical and Veterinary Affairs, Adrian Lock, expressed excitement for the upcoming study to further validate the therapy's efficacy. The company's CEO, Larry Heaton, believes the publication will accelerate the acceptance of shock wave therapy for small animal patients. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells, promoting healing growth factors. Zomedica's commitment to advancing veterinary care is evident through ongoing clinical studies and product innovations. The company's mission to address the unmet needs of clinical veterinarians underscores its dedication to animal welfare and better veterinary practice. For more information, readers can visit Zomedica's website. Zomedica Corp PulseVet Electro-hydraulic Shock Wave Therapy Veterinary Health Company Canine Patients Electro-hydraulic Shock Wave Therapy
PRESS RELEASE published on 01/04/2024 at 12:30, 2 years 10 months ago NanoViricides to Present at the Biotech Showcase in San Fransisco NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE published on 01/04/2024 at 12:00, 2 years 10 months ago Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan Tryp Therapeutics Inc. is pleased to announce the dosing of the first patient in a Phase 2a clinical trial for fibromyalgia using their proprietary IV-infused psilocin, TRP-8802. With positive results, the company aims to further develop TRP-8803 to provide relief to millions of patients suffering from chronic pain. Learn more about Tryp's innovative therapies at www.tryptherapeutics.com. Tryp Therapeutics Inc TRP-8802 Fibromyalgia IV-infused Psilocin Chronic Pain Relief
REGULATED PRESS RELEASE published on 01/04/2024 at 11:55, 2 years 10 months ago Edenred - Disclosure of Share Capital and Voting Rights as of December 31, 2023 This press release discloses the share capital and voting rights of Edenred as of December 31, 2023, in accordance with the French Commercial Code and the General Regulations of the Autorité des marchés financiers. The total shares outstanding, potential voting rights, and exercisable voting rights are provided, excluding rights attached to shares held in treasury. More information can be found on edenred.com, Investors/Shareholders section then Regulated Information. Edenred Share Capital Voting Rights French Commercial Code Investors
PRESS RELEASE published on 01/04/2024 at 08:00, 2 years 10 months ago Canadian Overseas Petroleum Ltd Announces Conversion of Bond Payments Canadian Overseas Petroleum Limited announces the issuance of 305,598,679 common shares for the settlement of Conversion Payment amounts. The Company now has a total of 1,344,370,498 common shares issued and outstanding. Shareholders may use this figure for the necessary calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Common Shares will be admitted to the FCA's Official List and to trading on the London Stock Exchange's main market for listed securities within the next twelve months. For further information, please refer to the contact details provided in the press release. Canadian Overseas Petroleum Limited Common Shares Issuance Conversion Payment Settlement London Stock Exchange Oil And Gas Exploration
PRESS RELEASE published on 01/04/2024 at 07:00, 2 years 10 months ago Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet. The publication highlights the positive results of Sarconeos (BIO101) in reducing the risk of death or respiratory failure in adults hospitalized with severe respiratory symptoms due to COVID-19. Biophytis will also host press conferences to discuss the potential and clinical benefits of Sarconeos (BIO101) in severe forms of COVID-19 and its exploration in the treatment of other respiratory viral infections. For more information, visit www.biophytis.com Biophytis COVA Phase 2-3 Study Sarconeos (BIO101) Publication Severe COVID-19 Treatment Respiratory Viral Infections Clinical Benefits Of Sarconeos (BIO101)
Published on 11/20/2026 at 15:00, 20 hours 18 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 20 hours 28 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 21 hours 18 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 21 hours 48 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 21 hours 48 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 11 hours 32 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 13 hours 41 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 15 hours 52 minutes ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 16 hours 14 minutes ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 16 hours 43 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 17 hours 43 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 16 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 2 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing